Hsbc Holdings PLC Makes New Investment in LifeStance Health Group, Inc. $LFST

Hsbc Holdings PLC acquired a new position in LifeStance Health Group, Inc. (NASDAQ:LFST) in the second quarter, HoldingsChannel reports. The firm acquired 119,006 shares of the company’s stock, valued at approximately $1,286,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Larson Financial Group LLC raised its position in LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after purchasing an additional 3,791 shares during the period. KBC Group NV bought a new stake in LifeStance Health Group in the first quarter worth $29,000. EverSource Wealth Advisors LLC boosted its position in LifeStance Health Group by 359.1% during the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after buying an additional 5,404 shares during the period. Bayesian Capital Management LP purchased a new stake in LifeStance Health Group during the second quarter valued at about $52,000. Finally, PNC Financial Services Group Inc. grew its stake in shares of LifeStance Health Group by 615.3% during the first quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock valued at $59,000 after buying an additional 7,987 shares during the last quarter. Institutional investors own 85.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Barclays lifted their price objective on LifeStance Health Group from $9.00 to $13.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. The Goldman Sachs Group assumed coverage on LifeStance Health Group in a report on Friday, June 5th. They set a “neutral” rating and a $9.00 target price for the company. Weiss Ratings upgraded LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, JPMorgan Chase & Co. boosted their price objective on LifeStance Health Group from $9.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, LifeStance Health Group has an average rating of “Moderate Buy” and a consensus price target of $12.38.

LifeStance Health Group Stock Performance

LifeStance Health Group stock opened at $12.36 on Tuesday. The stock’s 50 day simple moving average is $11.25 and its two-hundred day simple moving average is $8.65. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38. The stock has a market cap of $4.79 billion, a price-to-earnings ratio of 95.08 and a beta of 1.14. LifeStance Health Group, Inc. has a fifty-two week low of $4.77 and a fifty-two week high of $12.97.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. The firm had revenue of $435.35 million during the quarter, compared to analyst estimates of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The business’s revenue was up 26.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.01) EPS. As a group, analysts expect that LifeStance Health Group, Inc. will post 0.16 earnings per share for the current fiscal year.

Insider Transactions at LifeStance Health Group

In related news, COO Lisa K. Miller sold 47,912 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $519,845.20. Following the sale, the chief operating officer directly owned 281,289 shares of the company’s stock, valued at $3,051,985.65. This represents a 14.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $10.62, for a total value of $144,890,858.34. Following the completion of the transaction, the insider owned 98,101,407 shares of the company’s stock, valued at approximately $1,041,836,942.34. This trade represents a 12.21% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 14,629,850 shares of company stock valued at $154,952,012 in the last three months. Company insiders own 3.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.